Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

A Novel Therapeutic Approach In Acute Myeloid Leukemia (AML): In Vivo Preclinical Pharmacokinetic (PK), Pharmacodynamic (PD) and Antileukemia Activities Of Synthetic 2’-O-Methylphosphorothioate Mir-29b

Hongyan Wang, PhD, Ramasamy Santhanam, Ph.D, Zhiliang Xie, MD, Xiaomeng Huang, Ming Chiu, Mitch A. Phelps, PhD, Alison R Walker, MD, Michael A. Caligiuri, MD, Ramiro Garzon, MD, James Lee, PhD, Natarajan Muthusamy, DVM, Ph.D, Kenneth K. Chan, Ph.D, Guido Marcucci, MD

Blood (2013) 122 (21): 3933.

https://doi.org/10.1182/blood.V122.21.3933.3933

Published: 2013

Journal Articles

Targeting Mir-155 via The NEDD8-Activating Enzyme Inhibitor MLN4924: A Novel Therapeutic Approach For Acute Myeloid Leukemia (AML)

Jihane C Khalife, MS, Hanna S Radomska, PhD, Jennifer Saultz, MD, Ramasamy Santhanam, PhD, Xiaomeng Huang, Hongyan Wang, PhD, John P. Curfman, Yue-Zhong Wu, MS, Pia Hoellerbauer, Houda Alachkar, PharmD, PhD, Adrienne M Dorrance, Ph.D, Michael A. Caligiuri, MD, Ramiro Garzon, MD, Jason H. Mendler, MD, PhD, Guido Marcucci, MD

Blood (2013) 122 (21): 3804.

https://doi.org/10.1182/blood.V122.21.3804.3804

Published: 2013

Journal Articles

Phase I Study Of The Combination Of Midostaurin, Bortezomib and Chemotherapy In Relapsed/Refractory Acute Myeloid Leukemia (AML): Targeting Aberrant Tyrosine Kinase Activity

Alison R Walker, MD, Hongyan Wang, PhD, Rebecca Klisovic, MD, Katherine Walsh, MD, Sumithira Vasu, MBBS, Ramiro Garzon, MD, Steven M. Devine, MD, Amy Drake, William Blum, MD, Guido Marcucci, MD

Blood (2013) 122 (21): 3966.

https://doi.org/10.1182/blood.V122.21.3966.3966

Published: 2013

Journal Articles

Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML)

Hongyan Wang, Ping Chen, Ph.D., Jiang Wang, Ramasamy Santhanam, Ph.D, Josephine Aimiuwu, Vijayasaradhi UV, Zhongfa Liu, Sebastian Schwind, MD, Alice S. Mims, MD, Rebecca B Klisovic, MD, Alison Walker, MD, Michael R. Grever, MD, Miguel Villalona-Calero, MD, John C. Byrd, MD, Ramiro Garzon, MD, William Blum, MD, Kenneth K. Chan, Ph.D, Guido Marcucci, MD

Blood (2012) 120 (21): 3578.

https://doi.org/10.1182/blood.V120.21.3578.3578

Published: 2012

Journal Articles

Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results

Rebecca B Klisovic, MD, Hongyan Wang, Alison Walker, MD, Katherine Walsh, MD, Sumithira Vasu, MBBS, Ramiro Garzon, MD, Steven M. Devine, MD, Jiang Wang, Celia Garr, RN, Adam Norris, John C. Byrd, MD, Michael R. Grever, MD, William Blum, MD, Kenneth K. Chan, Ph.D, Guido Marcucci, MD

Blood (2012) 120 (21): 3616.

https://doi.org/10.1182/blood.V120.21.3616.3616

Published: 2012

Journal Articles

Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia

Blood (2012) 119 (25): 6025–6031.

https://doi.org/10.1182/blood-2012-03-413898

Published: 2012

Includes: Supplemental data

Journal Articles

RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia

Josephine Aimiuwu, Hongyan Wang, Ping Chen, Zhiliang Xie, Jiang Wang, Shujun Liu, Rebecca Klisovic, Alice Mims, William Blum, Guido Marcucci, Kenneth K. Chan

Blood (2012) 119 (22): 5229–5238.

https://doi.org/10.1182/blood-2011-11-382226

Published: 2012

Includes: Supplemental data

NARROW

A Novel Therapeutic Approach In Acute Myeloid Leukemia (AML): In Vivo Preclinical Pharmacokinetic (PK), Pharmacodynamic (PD) and Antileukemia Activities Of Synthetic 2’-O-Methylphosphorothioate Mir-29b

Targeting Mir-155 via The NEDD8-Activating Enzyme Inhibitor MLN4924: A Novel Therapeutic Approach For Acute Myeloid Leukemia (AML)

Phase I Study Of The Combination Of Midostaurin, Bortezomib and Chemotherapy In Relapsed/Refractory Acute Myeloid Leukemia (AML): Targeting Aberrant Tyrosine Kinase Activity

Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML)

Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results

Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia

RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

A Novel Therapeutic Approach In Acute Myeloid Leukemia (AML): In Vivo Preclinical Pharmacokinetic (PK), Pharmacodynamic (PD) and Antileukemia Activities Of Synthetic 2’-O-Methylphosphorothioate Mir-29b

Targeting Mir-155 via The NEDD8-Activating Enzyme Inhibitor MLN4924: A Novel Therapeutic Approach For Acute Myeloid Leukemia (AML)

Phase I Study Of The Combination Of Midostaurin, Bortezomib and Chemotherapy In Relapsed/Refractory Acute Myeloid Leukemia (AML): Targeting Aberrant Tyrosine Kinase Activity

Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML)

Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results

Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia

RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only